|D007153||Immunologic Deficiency Syndromes NIH||0.41|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This study is expected to provide, for the first time, data on Cov2-SARS circulation in asymptomatic children and children with moderate respiratory symptoms in order to construct the severity pyramid of this novel pathogen. This information will be essential in the coming weeks to understand the dynamics of the transmission of this pathogen at the population level and to highlight the relevance of public health interventions, particularly with regard to the systematic closure of schools and childcare facilities.
Description: Proportion of asymptomatic children or children with mild respiratory symptoms (mildly-symptomatic children) with a positive SARS-Cov2 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) on rhino pharyngeal swab or/and IgM/IgG positive serology in the Ile-de-France region during an epidemic period.Measure: Proportion of asymptomatic children or children with mild respiratory symptoms Time: 14 days
Description: The proportion of confirmed Cov2-SARS cases in mildly-symptomatic and asymptomatic children in different age groups (defined as 6-23 months, 2-4 years, 5-9 years, 10-15 years).Measure: Confirmed Cov2-SARS cases by age Time: 14 days
Description: The proportion of confirmed Cov2-SARS cases based on the symptoms presented by the patientsMeasure: Confirmed Cov2-SARS cases by symptoms Time: 14 days
Description: The viral load of children with SARS-Cov2 positive Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) depending on the symptoms and the age of the patientsMeasure: Viral load Time: 14 days
Description: The proportion of co-infection with other respiratory viruses among children with SARS -Cov2 RT-PCR positiveMeasure: Other respiratory viruses Time: 14 days
Description: Proportion of patients with Sars-Cov2 IgM +Measure: Sars-Cov2 IgM Time: 14 days
Description: Proportion of patients with Sars-Cov2 IgG +Measure: Sars-Cov2 IgG Time: 14 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports